Wishing all a joyful and safe American Independence Day filled with family, friends, and cherished memories. Let's come together and appreciate the blessings of liberty that we enjoy. #FourthofJuly
Velocity Clinical Research, Inc.
Biotechnology Research
Durham, North Carolina 21,480 followers
Delivering high-quality clinical trial data and patient care with unprecedented efficiency.
About us
Velocity is the world’s leading organization of fully integrated clinical research sites. With 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
- Website
-
https://velocityclinical.com
External link for Velocity Clinical Research, Inc.
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Clinical trials, Patient Recruitment, Vaccine Research, Pharmaceutical Research, Clinical Research, Vaccines, Neurology, Pediatrics, NASH, Infectious Disease, Dermatology, Women's Health, Gastroenterology, Alllergy, Medical Devices, Research Sites, Principal Investigators, and Drug Development
Locations
Employees at Velocity Clinical Research, Inc.
Updates
-
Velocity is proud to introduce a new site in St. Louis, our first in Missouri. The site will be co-located with West County Rheumatology, one of the largest and most active infusion centers in the Midwest, and a region-leading clinic for patients with rheumatoid arthritis, psoriatic arthritis, lupus, fibromyalgia, and hypermobility disorders. An elected Fellow of the American College of Rheumatology, Sona Kamat, MD, FACR, will serve as Principal Investigator for clinical trials at Velocity. The site will provide specialized support for rheumatology research, as well as a growing array of internal medicine and multi-therapeutic trials. #Rheumatology #ClinicalTrials #ClinicalResearch
-
-
In this edition of The Recap, Craig Koch provides an insightful introduction to our recent milestones, and what they mean for Velocity — and the industry — moving forward. Topics include: • Velocity’s entry into the U.S. oncology market • Another major achievement for our VISION technology • Our expanding capabilities and team of Principal Investigators in the U.K. Subscribe to The Recap here on LinkedIn or at https://lnkd.in/grZdGsK4
-
Obesity is a major growing health concern. Currently, 40% of the world’s population is considered overweight or obese, with the rate expected to hit 50% by 2035. Despite this trend, there is a growing body of evidence to suggest that providers spend less time, offer less education, and deprioritize building a rapport with these groups. Patients with obesity are frequently subjected to unsolicited advice, with their weight tending to drive medical conversations even when they seek treatment for an unrelated issue. Ensuring diversity, equity, and inclusion across our clinical trial sites is a core focus for the Velocity team. It is part of our three-year commitment to working towards 1:1 patient enrollment to match population demographics. Nadege Gunn, MD, CPI, is a principal investigator at Velocity’s site in Waco, Texas, who has been instrumental in building processes and protocols that are inclusive of the community living with obesity. She is board certified in obesity medicine, and is a leader of Velocity’s metabolic dysfunction-associated steatohepatitis (MASH) CARE Council. Hear from Dr. Gunn and discover how her work is driving equity and improving outcomes for all in the article below. #HealthcareEquity #ClinicalResearch #ObesityAwareness #InclusiveResearch #VelocityCares
Closing the gap: Breaking weight-based stigma in clinical trials
Velocity Clinical Research, Inc. on LinkedIn
-
Since launching in mid-2023, the first two VISION products have already contributed to more than 2,000 patient randomizations. VISION Recruit uses AI and advanced algorithms to match potential patients with specific study criteria. It can then automatically contact patients with the highest likelihood of eligibility. VISION Engage is a mobile app that empowers users to self-screen, manage appointments, and receive secure, in-app study stipend payments. Explore more about VISION: https://lnkd.in/gpZECMhS In this video: Paul Evans, President and CEO, and Nick Spittal, Chief Operations Officer
-
Paul Evans was featured in a Triangle Business Journal article covering Velocity’s recent partnership announcement with Luminis Health. As Paul notes in the article, hospitals play a crucial role in clinical research due to their patient populations, particularly in specialized fields like oncology. Velocity will take over the operation of the hospital’s existing clinical research capabilities in collaboration with Luminis Health’s world-class physician base. By doing so, Velocity will deliver increased efficiencies while bringing more clinical trials to a broader patient population. With oncology representing a significant portion of the industry's development pipeline, this expansion in the U.S. — along with Velocity’s existing oncology capabilities in Poland — will meet a growing client demand for Velocity’s site capabilities in this expansive therapeutic area. Read the full article: https://lnkd.in/gRjczwWy #Oncology #ClinicalTrials
-
-
On this significant day, we join the nation in commemorating Juneteenth and honoring the historic milestone of emancipation and freedom for African Americans. At Velocity Clinical Research, we stand in solidarity with the Black community, recognizing the ongoing struggle for racial justice and equality. Juneteenth serves as a reminder of the progress made and the work that still lies ahead to create a more inclusive society. As advocates for health equity, we are committed to breaking down barriers and addressing disparities in healthcare access and outcomes. We strive to conduct clinical research that represents diverse populations, including individuals from the Black community, to ensure that everyone has equal opportunities for optimal health. Together, let's continue to amplify Black voices, celebrate Black achievements, and work towards a future where equality and justice prevail. Happy Juneteenth! Learn more about our commitment to clinical research and health equity at https://buff.ly/3pQzE9t. #Juneteenth #HealthEquity #clinicalresearch #HealthForAll
-
-
If you’re at #DIA2024 today, make sure to catch Brittany Weichers, Executive Director of Patient Recruitment in a morning innovation theater session! Brittany, along with leaders from Fortrea, Advarra, and Veeva, will discuss how collaborative efforts are improving clinical trials by creating practical solutions for both site and patient challenges. Session: Teamwork Makes the Dream Work: How Partnering to Develop Practical Solutions that Address Site and Patient Challenges is Changing the Clinical Trial Landscape Date: Tuesday, June 18 Time: 11:55 a.m. - 12:25 p.m. Location: Exhibit Hall Theater 2, San Diego Convention Center #ClinicalTrials #Innovation #PatientRecruitment
-
-
"You’re starting from a trust deficit … People need to know that you care before they care what you know." In an internal presentation to Velocity, former Surgeon General Jerome Adams, MD, MPH reiterated the need for consistent community engagement to build trust and sustainable interest in clinical research. To support successful patient recruitment, outreach has to begin well before studies do. As Paul Evans mentions, "This is something that you do over a great deal of time." #PatientRecruitment #ClinicalTrials #Diversity #Inclusion
-
Today is Global Fatty Liver Day — a great day to highlight the importance of liver health and the progress being made in MASH and MASLD research! At Velocity, we're dedicated to advancing the understanding, screening, and treatment of liver diseases. Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, Nadege Gunn, MD, CPI, and J. Scott Overcash, M.D., our MASH CARE Council advises sites worldwide on best practices for steatotic liver disease trials. Many Velocity sites also offer free elastography and FibroScan screenings to help educate and engage communities about liver health and clinical research. Learn more about our MASH CARE Council: https://lnkd.in/gT3n_v5g #GlobalFattyLiverDay #LiverDisease #ClinicalTrials #HealthAwareness #LiverHealth #MASHDay
-